What happened
L&C BIO filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$27.5M (+88.4% year on year), operating profit of US$6.08M (from a loss a year earlier) and a net loss of US$19.9M.
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$27.5M |
|---|---|
| Revenue vs a year earlier | +88.4% |
| Operating profit | US$6.08M |
| Net income | −US$19.9M |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-08-11, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260811900225 → open original filing |
Source: DART. Information only, not investment advice.